S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
EXPLAINER: What's the effect of Russian oil price cap, ban?
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
EXPLAINER: What's the effect of Russian oil price cap, ban?
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
EXPLAINER: What's the effect of Russian oil price cap, ban?
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
EXPLAINER: What's the effect of Russian oil price cap, ban?
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
NASDAQ:ARGX

argenx - ARGX Stock Forecast, Price & News

$402.31
+3.09 (+0.77%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$396.00
$405.00
50-Day Range
$343.75
$402.31
52-Week Range
$249.50
$407.93
Volume
164,412 shs
Average Volume
245,952 shs
Market Capitalization
$22.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$430.14

argenx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
9.6% Upside
$440.92 Price Target
Short Interest
Healthy
1.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($15.20) to ($9.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

869th out of 1,034 stocks

Biological Products, Except Diagnostic Industry

144th out of 171 stocks

ARGX stock logo

About argenx (NASDAQ:ARGX) Stock

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Stock News Headlines

Argenx To Acquire FDA Priority Review Voucher - Quick Facts
Should You Invest in argenx SE (ARGX)?
Why Earnings Season Could Be Great for argenx (ARGX)
argenx Appoints Camilla Sylvest to Board of Directors
argenx to Present at Wells Fargo Healthcare Conference
See More Headlines
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Company Calendar

Last Earnings
10/27/2022
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/02/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
650
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$440.92
High Stock Price Forecast
$480.00
Low Stock Price Forecast
$340.00
Forecasted Upside/Downside
+6.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
14 Analysts

Profitability

Net Income
$-408,270,000.00
Net Margins
-295.08%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$539.42 million
Book Value
$49.05 per share

Miscellaneous

Free Float
53,980,000
Market Cap
$22.26 billion
Optionable
Optionable
Beta
0.79

Key Executives

  • Mr. Timothy Van Hauwermeiren EMBA (Age 50)
    M.B.A., M.Sc., MSc, CEO & Exec. Director
    Comp: $1.28M
  • Prof. Hans de Haard Ir (Age 62)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Mr. Karl Gubitz (Age 52)
    Chief Financial Officer
  • Mr. R. Keith Woods (Age 54)
    Chief Operating Officer
  • Mr. Arjen Lemmen M.Sc. (Age 37)
    VP of Corp. Devel. & Strategy
  • Dr. David L. Lacey M.D. (Age 70)
    Advisor
    Comp: $19.71k
  • Ms. Andria Wilk (Age 48)
    Global Head of Quality
  • Mr. Filip Borgions
    VP & Global Head of Technical Operations
  • Ms. Beth DelGiacco
    VP and Global Head of Corp. Communications & Investor Relations
  • Ms. Malini Moorthy (Age 52)
    Gen. Counsel













ARGX Stock - Frequently Asked Questions

Should I buy or sell argenx stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARGX shares.
View ARGX analyst ratings
or view top-rated stocks.

What is argenx's stock price forecast for 2023?

14 equities research analysts have issued 1-year price objectives for argenx's shares. Their ARGX share price forecasts range from $340.00 to $480.00. On average, they anticipate the company's stock price to reach $440.92 in the next twelve months. This suggests a possible upside of 9.6% from the stock's current price.
View analysts price targets for ARGX
or view top-rated stocks among Wall Street analysts.

How have ARGX shares performed in 2022?

argenx's stock was trading at $350.19 at the start of the year. Since then, ARGX shares have increased by 14.9% and is now trading at $402.31.
View the best growth stocks for 2022 here
.

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our ARGX earnings forecast
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) posted its earnings results on Thursday, October, 27th. The company reported ($4.26) EPS for the quarter, missing analysts' consensus estimates of ($3.50) by $0.76. The firm had revenue of $146.49 million for the quarter, compared to analysts' expectations of $115.49 million. argenx had a negative net margin of 295.08% and a negative trailing twelve-month return on equity of 49.53%.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

Who are argenx's major shareholders?

argenx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.66%), Artisan Partners Limited Partnership (5.11%), Jennison Associates LLC (2.80%), Bellevue Group AG (1.66%), BlackRock Inc. (1.45%) and Pictet Asset Management SA (0.91%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $402.31.

How much money does argenx make?

argenx (NASDAQ:ARGX) has a market capitalization of $22.26 billion and generates $539.42 million in revenue each year. The company earns $-408,270,000.00 in net income (profit) each year or ($17.19) on an earnings per share basis.

How many employees does argenx have?

The company employs 650 workers across the globe.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for the company is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at info@argenx.com.

This page (NASDAQ:ARGX) was last updated on 12/3/2022 by MarketBeat.com Staff